Healthcare/ Diagnostics/ Article

Editorial Article

Sysmex Took 1.7 Per Cent Off Sales and 40.8 Per Cent Off Operating Profit

Updated November 12, 2026

A 1.7% revenue decline cannot produce a 40.8% operating profit decline through volume. Something else did it, and what it was is the whole economics of the discipline.

The arithmetic that rules out the obvious explanation

Sysmex closed the year to 31 March 2026 with net sales of JPY 500,006 million, down 1.7%, and operating profit of JPY 51,831 million, down 40.8%. The operating margin went from 17.2% to 10.4% in twelve months. The prior year the same company grew sales 10.2% and operating profit 11.7%.

If cost were strictly proportional to revenue, a 1.7% revenue decline removes 1.7% of cost and roughly 1.7% of profit. To lose 40.8% of profit on a 1.7% volume shortfall you need a cost base that did not move with the revenue. That is not an anomaly in this business. It is the design of it.

What an analyser business costs when the per-test price falls

Every reagent-led diagnostics franchise is two businesses wearing one name. The instrument is a capital commitment placed at or near cost, amortised over five to ten years of expected reagent consumption. The reagent is an annuity that pays the instrument back. Both halves are fixed in the short run: the placement has been made, the service engineer and application specialist have been assigned, the distribution and the field force exist at a size set by the installed base rather than by last quarter’s volume.

So when the price per reportable result falls, the annuity per instrument falls while the cost of having placed it does not. The margin compression is not a percentage of the price decline — it is the price decline divided by a much smaller operating margin, and then leveraged again by the fact that placements continue. A company that keeps placing instruments into a falling per-test price is buying future annuity at yesterday’s price. That is precisely how a 1.7% revenue line becomes a 40.8% profit line.

Three disclosures, one mechanism

Company and period What it disclosed Direction
Sysmex, year to 31 March 2026 Net sales JPY 500.0bn; operating profit JPY 51.8bn; operating margin 10.4% against 17.2% Sales −1.7%, operating profit −40.8%
Dirui Industrial, calendar 2025 Revenue RMB 807.1m; attributable net loss RMB 246.0m; qualified audit opinion and adverse internal-control opinion; prior-year comparatives restated for an accounting error correction Revenue −17.41%, profit to loss
Mindray, IVD segment 2025 Segment revenue; domestic against international split disclosed Segment −9.41%; domestic −22.97%, international +7.40%
Roche, 2025 core laboratory Core lab flat at CHF 7.6bn with clinical chemistry +7% and immuno-diagnostics −3% Split within a flat total
Abbott, 2025 Core Laboratory Organic growth, with the US and international separated +2.1% organic; US +7.0%, international +0.4%
QuidelOrtho, 2025 Labs Constant-currency growth against a shrinking group Labs +5.7%; group −2.1%

Dirui is the cleanest read because it is the closest thing anywhere to a pure-play chemistry-and-urinalysis vendor. Its 2025 was not a bad quarter inside a diversified group; it was the whole company, in the two product lines with the least room to differentiate, in the market that repriced hardest. It posted a loss, its auditor qualified the opinion, and the internal-control opinion was adverse. A pure-play takes the full force of a price reset that a diversified vendor can absorb across a menu. That is what the concentration variable looks like from the inside.

Mindray is the controlled experiment. The same company, the same products, the same reporting period: the domestic IVD business fell 22.97% while the international business grew 7.40%. The product did not change between those two numbers. The price regime did.

Who grew, and why the answer is menu rather than chemistry

The comfortable reading of 2025 is that chemistry is a bad business. The disclosures do not support it. Roche’s clinical chemistry line grew 7% inside a core laboratory total that was flat — meaning the immunoassay line inside the same franchise must have fallen, and the only weight on those two lines that reconciles CHF 7.6 billion of zero growth with +7% and −3% is roughly 70/30. Abbott’s Core Laboratory grew 2.1% organically with the United States at +7.0%, in a year when Chinese volume-based procurement was explicitly named as a drag. QuidelOrtho’s Labs segment grew 5.7% at constant currency inside a group that shrank 2.1%.

What separates that set from Dirui and from Sysmex’s year is not the analyte. It is three things: a menu wide enough that a buyer cannot price-compare every line item, a geography where the price is negotiated rather than awarded, and an installed base large enough that service and consumables carry the margin the test no longer does. Chemistry does not fail. Un-differentiated chemistry sold into an administered price fails.

Which is also why the immunoassay side of the same franchises looks worse than the chemistry side in 2025. Immunoassay has the higher gross margin, and therefore the further to fall when an alliance sets the price. Our own base construction for this cluster puts immunoassay at USD 26.4 billion growing 4.90% and clinical chemistry and urinalysis at USD 16.8 billion growing 3.71% — the slower-growing discipline is the one carrying the lower margin, which is exactly what you would expect if price, not demand, is the binding constraint.

Sysmex’s specific exposure: a panel with no trade-up

Sysmex is the global leader in urinalysis, and urinalysis is the one chemistry-adjacent discipline where the product is a fixed panel. A dipstick has no menu to trade up into: ten or eleven pads, one price, and no clinical argument for a premium version. Sediment analysers took the labour out of microscopy and captured that value once — the analyser was priced on labour saved, and once the labour was saved the saving stopped compounding.

So the only lever left in urinalysis is cost, and cost reduction is a one-time gift. A group that had already harvested its automation saving and then met a falling per-test price has nothing left to pull except volume, and volume does not pay for a fixed base when the price per result is falling faster than the result count is rising. Watch where the value goes next: the quantitative albumin assay, which is guideline-mandated, serial, and priced as chemistry rather than as a strip.

What this does to a 3.71% forecast, and what would break it

Our base case for clinical chemistry and urinalysis is USD 16.8 billion in 2025 to USD 22.49 billion in 2033 at 3.71%, on reportable results growing 5.13% a year while realised revenue per result falls from USD 0.78 to USD 0.70. Every figure above is consistent with that. Volume grows. Revenue per unit falls. The margin gets squeezed from both sides. Anyone modelling this discipline off unit growth alone will overstate it by roughly the gap between 5.13% and 3.71%.

The falsifier is the operating margin itself. If the vendors holding the widest menus and the most US-weighted revenue hold margin through the 2027 fee-schedule reset, then the compression is a China story and a pure-play story rather than a discipline-wide one. If Sysmex’s margin does not recover toward the mid-teens once the one-off cost items in the year to March 2026 annualise out, then the cost base was never flexible and the whole category trades at a permanently lower margin — with the 3.71% rate intact and a materially worse profit pool sitting underneath it.

Companion analyses in this cluster

About the method

70/30, secondary to primary. The financial figures here are taken from the companies’ own filings: Sysmex’s consolidated results for the years ended 31 March 2025 and 31 March 2026, Dirui Industrial’s 2025 annual report, Mindray’s 2025 annual report, Roche’s 2025 annual report, Abbott’s and QuidelOrtho’s fourth-quarter 2025 releases. Note the measures are not identical and are not treated as if they were: Sysmex reports IFRS group figures that include non-diagnostics businesses, Dirui’s 2025 comparatives were restated for an accounting error correction and its audit opinion was qualified, Abbott’s figure is organic growth, and Roche’s growth rates are at constant exchange rates. Our primary programme for the underlying report — 41 depth interviews across 11 markets, 26 open-ended tender interviews, a 164-respondent laboratory survey and four conferences — is used for mechanism only: why a laboratory renegotiates at contract renewal, why a distributor carries a margin the vendor no longer can, and why a field force is sized to placements rather than to revenue. It carries no figure. These programme parameters are stated so they can be reconciled against programme records.

Sources

No third-party market-research estimate is used in this analysis. Vendor revenue that a company does not disclose separately is treated in this cluster as a stated residual, not inferred from an external forecast.

Frequently Asked Questions

How did Sysmex's operating profit fall 40.8% on a 1.7% sales decline?

Because the cost base does not move with revenue. In a reagent-led diagnostics franchise the instrument is placed at or near cost and amortised over years of expected reagent consumption, while the service engineer, application specialist and field force are sized to the installed base rather than to last quarter's volume. When the price per reportable result falls, the annuity per instrument falls and the cost of having placed it does not. Sysmex's net sales were JPY 500,006 million, down 1.7%, operating profit JPY 51,831 million, down 40.8%, and the operating margin 10.4% against 17.2% a year earlier.

What does Dirui's 2025 result show?

It shows what a pure-play absorbs. Revenue fell 17.41% to RMB 807.06 million and the company moved from a restated attributable profit of RMB 65.16 million to a net loss of RMB 245.99 million, with a qualified audit opinion and an adverse internal-control opinion, after restating prior-year comparatives for an accounting error correction. Dirui is the closest thing listed anywhere to a chemistry-and-urinalysis pure-play, in the two product lines with the least room to differentiate.

If chemistry prices are falling, why did Roche, Abbott and QuidelOrtho grow?

Menu breadth and geography. Roche's clinical chemistry line grew 7% inside a core laboratory that was flat, which means the immunoassay line inside it fell. Abbott's Core Laboratory grew 2.1% organically with the United States up 7.0% and international up 0.4%. QuidelOrtho's Labs segment grew 5.7% at constant currency inside a group that shrank 2.1%. What separates them from Dirui and from Sysmex's year is a menu wide enough that a buyer cannot price-compare every line, a market where price is negotiated rather than awarded, and service revenue on a large installed base.

What would show the margin compression is permanent rather than cyclical?

The operating margin itself. If Sysmex's margin recovers toward the mid-teens once the one-off cost items in the year to March 2026 annualise out, the compression was cyclical and specific to a pure-play and to China. If it does not recover, the cost base was never flexible and the discipline trades at a permanently lower margin — with the 3.71% revenue growth rate intact and a materially smaller profit pool sitting underneath it.